December 5, 2022 - 8-K: Current report filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 30, 2022

APOLLO MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-37392

95-4472349

(State or Other Jurisdiction

(Commission

(I.R.S. Employer

of Incorporation)

File Number)

Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			☐			Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			☐			Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02			Departure of Directors or Certain Oﬃcers; Election of Directors; Appointment of Certain Oﬃcers; Compensatory Arrangements of Certain Oﬃcers.

On November 30, 2022, Apollo Medical Holdings, Inc. (together with its subsidiaries and affiliated entities, “Company”) appointed John Vong as the Company’s Chief Accounting Officer.

Mr. Vong, 49, joined the Company in July 2022 as its Vice-President of Finance and Accounting. Prior to joining the Company, Mr. Vong served as Vice President of Finance and Accounting at Prospect Medical Systems, Inc. from February 2016 to July 2022. Mr. Vong began his career as a certified public accountant with RSM. Mr. Vong received a Bachelor of Science degree in Business Administration from the University of California, Riverside and a Master of Business Administration degree from the University of California, Irvine.

In connection with Mr. Vong’s appointment, the Company entered into an employment agreement with Mr. Vong, providing the terms of his employment, including an annual base salary comparable in amount to the Company's other senior management with similar qualifications, experiences and responsibilities, equity awards and other employee benefits, as well as eligibility for an annual bonus.

The selection of Mr. Vong to serve as Company’s Chief Accounting Officer was not made pursuant to any arrangement or understanding with any other person. Mr. Vong has no familial relationships with any executive officer or director of the Company. There have been no transactions in which the Company has participated and in which Mr. Vong had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.


Item 9.01			Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.						Description
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	APOLLO MEDICAL HOLDINGS, INC.

Date: December 5, 2022	By:	/s/ Thomas S. Lam
	Name: Title:	Thomas S. Lam, M.D., M.P.H. Co-Chief Executive Officer and President